Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Rhea-AI Summary

Talphera (NASDAQ: TLPH) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025. The specialty pharmaceutical company, focused on developing innovative therapies for medically supervised settings, will host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard.

The webcast will feature a slide presentation and can be accessed through the company's website at www.talphera.com in the Investors/News & Events/Upcoming Events section. A replay will be available for 90 days following the event. Investors can join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using conference ID 11814.

SAN MATEO, Calif., March 26, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.

Webcast Information

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 11814.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-fourth-quarter-and-full-year-2024-financial-results-and-corporate-update-call-and-webcast-on-monday-march-31-2025-302412500.html

SOURCE Talphera, Inc.

FAQ

When will Talphera (TLPH) release its Q4 and full-year 2024 earnings?

Talphera will release its Q4 and full-year 2024 financial results after market close on Monday, March 31, 2025.

What time is Talphera's (TLPH) Q4 2024 earnings call?

The earnings call and webcast will take place at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard on March 31, 2025.

How can investors access Talphera's (TLPH) Q4 2024 earnings webcast?

Investors can access the webcast through Talphera's website (www.talphera.com) in the Investors/News & Events/Upcoming Events section.

What is the conference call dial-in number for Talphera's (TLPH) Q4 2024 earnings?

North American investors can dial 1-800-836-8184, while international callers should use 1-646-357-8785 (toll applies). The conference ID is 11814.